AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

Cash and Equivalents

Cash and Equivalents %Chg

Cash and Equivalents Common Size

Short-Term Investments

Short-Term Investments %Chg

Short-Term Investments Common Size

Accounts Receivable, Net

Accounts Receivable, Net %Chg

Accounts Receivable, Net Common Size

Inventories

Inventories %Chg

Inventories Common Size

Prepaid Expenses and Other

Prepaid Expenses and Other %Chg

Prepaid Expenses and Other Common Size

Total Current Assets

Total Current Assets %Chg

Total Current Assets Common Size

Investments

Investments %Chg

Investments Common Size

Property and Equipment, Net

Property and Equipment, Net %Chg

Property and Equipment, Net Common Size

Intangible Assets, Net

Intangible Assets, Net %Chg

Intangible Assets, Net Common Size

Goodwill

Goodwill %Chg

Goodwill Common Size

Other Assets

Other Assets %Chg

Other Assets Common Size

Total Assets

Total Assets %Chg

Total Assets Common Size

Short-Term Borrowings

Short-Term Borrowings %Chg

Short-Term Borrowings Common Size

Current Portion of Long-Term Debt and Finance Lease Obligations

Current Portion of Long-Term Debt and Finance Lease Obligations %Chg

Current Portion of Long-Term Debt and Finance Lease Obligations Common Size

Accounts Payable and Accrued Liabilities

Accounts Payable and Accrued Liabilities %Chg

Accounts Payable and Accrued Liabilities Common Size

Total Current Liabilities

Total Current Liabilities %Chg

Total Current Liabilities Common Size

Long-Term Debt and Finance Lease Obligations

Long-Term Debt and Finance Lease Obligations %Chg

Long-Term Debt and Finance Lease Obligations Common Size

Deferred Income Taxes

Deferred Income Taxes %Chg

Deferred Income Taxes Common Size

Other Long-Term Liabilities

Other Long-Term Liabilities %Chg

Other Long-Term Liabilities Common Size

Common Stock

Common Stock %Chg

Common Stock Common Size

Common Stock Held in Treasury, at Cost

Common Stock Held in Treasury, at Cost %Chg

Common Stock Held in Treasury, at Cost Common Size

Additional Paid-in Capital

Additional Paid-in Capital %Chg

Additional Paid-in Capital Common Size

Retained Earnings

Retained Earnings %Chg

Retained Earnings Common Size

Accumulated Other Comprehensive Loss

Accumulated Other Comprehensive Loss %Chg

Accumulated Other Comprehensive Loss Common Size

Total Stockholders' Equity

Total Stockholders' Equity %Chg

Total Stockholders' Equity Common Size

Noncontrolling Interest

Noncontrolling Interest %Chg

Noncontrolling Interest Common Size

Total Equity

Total Equity %Chg

Total Equity Common Size

Total Liabilities and Equity

Total Liabilities and Equity %Chg

Total Liabilities and Equity Common Size

Cash and Cash Equivalents

Cash and Cash Equivalents %Chg

Cash and Cash Equivalents Common Size

Total Cash and Cash Equivalents

Total Cash and Cash Equivalents %Chg

Total Cash and Cash Equivalents Common Size

Accounts Receivable

Accounts Receivable %Chg

Accounts Receivable Common Size

Total Trade Receivables

Total Trade Receivables %Chg

Total Trade Receivables Common Size

Other Current Assets

Other Current Assets %Chg

Other Current Assets Common Size

Net Property, Plant & Equipment

Net Property, Plant & Equipment %Chg

Net Property, Plant & Equipment Common Size

Net Intangible Assets

Net Intangible Assets %Chg

Net Intangible Assets Common Size

Long-Term Investments

Long-Term Investments %Chg

Long-Term Investments Common Size

Other Long-Term Assets

Other Long-Term Assets %Chg

Other Long-Term Assets Common Size

Accounts Payable

Accounts Payable %Chg

Accounts Payable Common Size

Short-Term Debt

Short-Term Debt %Chg

Short-Term Debt Common Size

Current Portion of Long-Term Debt

Current Portion of Long-Term Debt %Chg

Current Portion of Long-Term Debt Common Size

Revenue

EBIT

EBITDA

CapEx

Net Interest Income

Assets

Adjusted EBITDA

Gross Profit

Adjusted Net Income

Net Revenue

Net Income

Average Assets

Adjusted EBIT

Adjusted Revenue

Adjusted EBT

Adjusted Funds From Operations

Assets	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Cash and Cash Equivalents	6,467	5,524	13,130	12,814	8,759	9,201
Cash and Equivalents
Short-Term Investments	—	31	27	2	7	28
Short-Term Investments
Total Cash and Cash Equivalents	6,467	5,555	13,157	12,816	8,766	9,229
Accounts Receivable	12,637	10,919	11,724	11,155	11,491	11,254
Accounts Receivable, Net
Total Trade Receivables	12,637	10,919	11,724	11,155	11,491	11,254
Inventories	4,960	4,181	4,218	4,099	4,055	3,579
Inventories
Other Current Assets	5,197	4,927	4,717	4,932	4,540	4,401
Prepaid Expenses and Other
Total Current Assets	29,261	25,582	33,816	33,002	28,852	28,463
Total Current Assets
Net Property, Plant & Equipment	5,283	5,134	5,023	4,989	4,943	4,935
Property and Equipment, Net
Net Intangible Assets	57,031	60,068	60,243	55,610	62,862	67,439
Intangible Assets, Net
Goodwill	35,638	34,956	33,386	32,293	32,224	32,156
Goodwill
Long-Term Investments	310	279	272	304	288	241
Investments
Other Long-Term Assets	9,659	9,142	9,197	8,513	6,198	5,571
Other Assets
Total Assets	137,182	135,161	141,937	134,711	135,367	138,805
Total Assets

Liabilities	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Accounts Payable	32,245	31,945	29,329	30,650	27,036	25,402
Accounts Payable and Accrued Liabilities
Short-Term Debt	5,556	—	—	—	—	1
Short-Term Borrowings
Current Portion of Long-Term Debt	1,966	6,804	12,586	7,191	5,203	4,135
Current Portion of Long-Term Debt and Finance Lease Obligations
Total Current Liabilities	39,767	38,749	41,915	37,841	32,239	29,538
Total Current Liabilities
Long-Term Debt	62,959	60,340	58,048	52,194	55,812	59,135
Long-Term Debt and Finance Lease Obligations
Other Long-Term Liabilities	34,594	32,708	35,153	34,279	34,418	32,845
Deferred Income Taxes
Other Long-Term Liabilities
Total Long-Term Liabilities	97,553	93,048	93,201	86,473	90,230	91,980
Total Liabilities	137,320	131,797	135,116	124,314	122,469	121,518

Equity	Jun '25	Dec '24	Jun '24	Dec '23	Jun '23	Dec '22
Common Stock	18	18	18	18	18	18
Common Stock
Treasury Stock	-9,147	-8,201	-7,838	-6,533	-6,528	-4,594
Common Stock Held in Treasury, at Cost
Additional Paid-in Capital	21,987	21,333	20,879	20,180	19,839	19,245
Additional Paid-in Capital
Accumulated Other Comprehensive Income	-1,538	-1,925	-2,513	-2,305	-2,252	-2,199
Accumulated Other Comprehensive Loss
Retained Earnings	-11,503	-7,900	-3,768	-1,000	1,789	4,784
Retained Earnings
Total Common Shareholders' Equity	-183	3,325	6,778	10,360	12,866	17,254
Total Stockholders' Equity
Minority Interests and Other	45	39	43	37	32	33
Noncontrolling Interest
Total Shareholders' Equity	-138	3,364	6,821	10,397	12,898	17,287
Total Equity
Total Liabilities and Shareholders' Equity	137,182	135,161	141,937	134,711	135,367	138,805
Total Liabilities and Equity